Patients with community-acquired bacteremia of unknown origin: clinical characteristics and usefulness of microbiological results for therapeutic issues: a single-center cohort study

Johan Courjon, Elisa Demonchy, Nicolas Degand, Karine Risso, Raymond Ruimy, Pierre-Marie Roger, Johan Courjon, Elisa Demonchy, Nicolas Degand, Karine Risso, Raymond Ruimy, Pierre-Marie Roger

Abstract

Bacteremia of unknown origin (BUO) are associated with increased mortality compared to those with identified sources. Microbiological data of those patients could help to characterize an appropriate empirical antibiotic treatment before bloodcultures results are available during sepsis of unknown origin. Based on the dashboard of our ward that prospectively records several parameters from each hospitalization, we report 101 community-acquired BUO selected among 1989 bacteremic patients from July 2005 to April 2016, BUO being defined by the absence of clinical and paraclinical infectious focus and no other microbiological samples retrieving the bacteria isolated from blood cultures. The in-hospital mortality rate was 9%. We retrospectively tested two antibiotic associations: amoxicillin-clavulanic acid + gentamicin (AMC/GM) and 3rd generation cephalosporin + gentamicin (3GC/GM) considered as active if the causative bacteria was susceptible to at least one of the two drugs. The mean age was 71 years with 67% of male, 31 (31%) were immunocompromised and 52 (51%) had severe sepsis. Eleven patients had polymicrobial infections. The leading bacterial species involved were Escherichia coli 25/115 (22%), group D Streptococci 12/115 (10%), viridans Streptococci 12/115 (10%) and Staphylococcus aureus 11/115 (9%). AMC/GM displayed a higher rate of effectiveness compared to 3GC/GM: 100/101 (99%) vs 94/101 (93%) (p = 0.04): one Enterococcus faecium strain impaired the first association, Bacteroides spp. and Enterococcus spp. the second. In case of community-acquired sepsis of unknown origin, AMC + GM should be considered.

Keywords: Antimicrobial resistance; Bacteremia; Bacteremia of unknown origin; Empirical antibiotic treatment; Primary bacteremia; Severe sepsis.

Figures

Fig. 1
Fig. 1
Selection of the patients with a bacteremia of unknown origin (BUO)

References

    1. Viscoli C. Bloodstream infections: the peak of the iceberg. Virulence. 2016;7:248–251. doi: 10.1080/21505594.2016.1152440.
    1. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584–602. doi: 10.1093/clind/24.4.584.
    1. Renaud B, Brun-Buisson C, Group IC-BS Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–1590. doi: 10.1164/ajrccm.163.7.9912080.
    1. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–1624. doi: 10.1378/chest.123.5.1615.
    1. Hernandez C, Cobos-Trigueros N, Feher C, et al. Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1973–1980. doi: 10.1007/s10096-014-2146-3.
    1. Pedersen G, Schonheyder HC, Sorensen HT. Source of infection and other factors associated with case fatality in community-acquired bacteremia—a Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect. 2003;9:793–802. doi: 10.1046/j.1469-0691.2003.00599.x.
    1. Adrie C, Garrouste-Orgeas M, Ibn Essaied W, et al. Attributable mortality of ICU-acquired bloodstream infections: impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. J Infect. 2017;74:131–141. doi: 10.1016/j.jinf.2016.11.001.
    1. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Fernandez-Delgado E, Lopez-Sanchez JM. Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality. Crit Care. 2015;19:302. doi: 10.1186/s13054-015-1000-z.
    1. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008;14(Suppl 1):144–153. doi: 10.1111/j.1469-0691.2007.01850.x.
    1. Roger PM, Farhad R, Leroux S, et al. Gestion de services, tarification à l’activité, recherche clinique et évaluation des pratiques professionnelles: un même outil informatique. Med Mal Infect. 2008;38:457–464. doi: 10.1016/j.medmal.2008.06.027.
    1. Comité de l’antibiogramme de la société Française de Microbiologie. .
    1. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27:870–926. doi: 10.1128/CMR.00109-13.
    1. Ortega M, Almela M, Martinez JA, et al. Epidemiology and outcome of primary community-acquired bacteremia in adult patients. Eur J Clin Microbiol Infect Dis. 2007;26:453–457. doi: 10.1007/s10096-007-0304-6.
    1. Chirouze C, Schuhmacher H, Rabaud C, et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis. 2002;35:156–161. doi: 10.1086/341023.
    1. Knudtzen FC, Nielsen SL, Gradel KO, et al. Characteristics of patients with community-acquired bacteremia who have low levels of C-reactive protein (</=20 mg/L) J Infect. 2014;68:149–155. doi: 10.1016/j.jinf.2013.10.006.
    1. Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M. Bacteremia and fungemia of unknown origin in adults. Clin Infect Dis. 1992;14:436–443. doi: 10.1093/clinids/14.2.436.
    1. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:795. doi: 10.1186/s13054-015-0795-y.
    1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. .
    1. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011;17:1581–1586. doi: 10.1111/j.1469-0691.2010.03425.x.
    1. Lemonovich TL, Haynes K, Lautenbach E, Amorosa VK. Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study. Infection. 2011;39:549–554. doi: 10.1007/s15010-011-0189-2.
    1. Contou D, Roux D, Jochmans S, et al. Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study. Crit Care. 2016;20:360. doi: 10.1186/s13054-016-1537-5.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren